Imatinib has adverse effect on growth in children with chronic myeloid leukemia

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 481-484

  Bansal, Deepak ^a   Shava, Upender ^a   Varma, Neelam ^a   Trehan, Amita ^a   Marwaha, R K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Growth hormone; Height; Short stature; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB;

ADOLESCENT; ARTICLE; CANCER SURVIVAL; CHILD; CHILD GROWTH; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GROWTH DISORDER; HEIGHT; HUMAN; INDIA; MALE; OUTCOME ASSESSMENT; PREPUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84863865642     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23389     Document Type: Article

References (23)

1. Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011; 17: S115-S122.
2. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 2008; 42: S40-S46.
3. Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: Does it really matter? Leuk Lymphoma 2006; 47: 1-7.
4. Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation. Hematol Am Soc Hematol Educ Program 2010; 2010: 368-376.
5. Kanavos P, Vandoros S, Garcia-Gonzalez P. Benefits of global partnerships to facilitate access to medicines in developing countries: A multi-country analysis of patients and patient outcomes in GIPAP. Global Health 2009; 5: 19.
6. Mariani S, Giona F, Basciani S, et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008; 372: 111-112.
7. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009; 89: 251-252.
8. Schmid H, Jaeger B, Lohse J, et al. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009; 94: 1177-1179.
9. Millot F, Baruchel A, Guilhot J, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CP): Results of the French National Phase IV trial. Blood (ASH Annu Meet Abstr) 2009; 114: Abstract 863.
10. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159: 676-681.
11. Hobernicht SL, Schweiger B, Zeitler P, et al. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer 2011; 56: 671-673.
12. Tanner JM. Growth at adolescence, 2nd edition. Oxford, England: Blackwell Scientific Publications; 1962.
13. WHO. AnthroPlus for personal computers: Software for assessing growth of the world's children and adolescents. Geneva: WHO; 2009.
14. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
15. Vandyke K, Fitter S, Dewar A, et al. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010; 115: 766-774.
16. Berman E, Nicolaides M, Maki R, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013.
17. Vandyke K, Dewar AL, Fitter S, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009; 23: 2155-2159.
18. Suttorp M, Thiede C, Tauer JT, et al. Chronic myeloid leukemia in pediatrics-First results from study CML-PAED II. Blood (ASH Annu Meet Abstr) 2009; 114: Abstract 145.
19. Tauer JT, Jaeger BAS, Suttorp M. Alterations of bone metabolic parameters in children and adolescents with chronic myeloid leukemia under prolonged treatment with the tyrosine kinase inhibitor imatinib [Abstract]. Proceedings of the 7th International Workshop of Musculoskeletal and Neuronal Interactions 2010; Hylonome, Athens, Greece, pp. 32-33.
20. Kebapcilar L, Bilgir O, Alacacioglu I, et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med Princ Pract 2009; 18: 360-363.
21. Sanders JE. Growth and development after hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas' hematopoietic cell transplantation. Chichester: Wiley-Blackwell; 2009. pp. 1608-1610.
22. Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57: 56-62.
23. Muramatsu H, Kojima S, Yoshimi A, et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Biol Blood Marrow Transplant 2010; 16: 231-238.